Insider Trading Alert - Ironwood Pharmaceuticals And 3 Others Traded By Insiders

Yesterday, July 8, 2013, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1.15 to $10,873,958.42.

Highlighted Stocks Traded by Insiders:

Ironwood Pharmaceuticals (IRWD) - FREE Research Report

Hecht Peter M who is Chief Executive Officer at IRONWOOD PHARMA bought 184,758 shares at $0.20 per share for a total value of $60,000.00 on July 8, 2013. Following this transaction, the Chief Executive Officer owned 7.5 million shares meaning that the stake was boosted by 2.51% with the 184,758 share acquisition.

The shares most recently traded at $10.52, down $0.03, or 0.28% since the insider transaction.

The average volume for Ironwood Pharmaceuticals has been 1.3 million shares per day over the past 30 days. Ironwood Pharmaceuticals has a market cap of $981.3 million and is part of the health care sector and health services industry. Shares are down 5.42% year to date as of the close of trading on Monday.

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Currently there are 3 analysts that rate Ironwood Pharmaceuticals a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRWD - FREE

TheStreet Quant Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Ironwood Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

AGCO (AGCO) - FREE Research Report

Srinivasan Mallika who is Director at AGCO CORP bought 5.1 million shares at $16.66 per share for a total value of $414,834.00 on July 5, 2013. Following this transaction, the Director owned 5.8 million shares meaning that the stake was boosted by 761.52% with the 5.1 million share acquisition.

The shares most recently traded at $52.28, up $1.02, or 1.99% since the insider transaction. Historical insider transactions for AGCO go as follows:

  • 4-Week # shares sold: 2,739
  • 12-Week # shares bought: 3,920
  • 12-Week # shares sold: 25,339
  • 24-Week # shares bought: 3,920
  • 24-Week # shares sold: 36,445

The average volume for AGCO has been 937,700 shares per day over the past 30 days. AGCO has a market cap of $4.9 billion and is part of the industrial goods sector and industrial industry. Shares are up 4.36% year to date as of the close of trading on Monday.

AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The stock currently has a dividend yield of 0.79%. The company has a P/E ratio of 9.5. Currently there are 5 analysts that rate AGCO a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGCO - FREE

TheStreet Quant Ratings rates AGCO as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full AGCO Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Carrizo Oil & Gas (CRZO) - FREE Research Report

Johnson S P Iv who is President and CEO at CARRIZO OIL&GAS sold 6,000 shares at $30.00 per share for a total value of $180,000.00 on July 5, 2013. Following this transaction, the President and CEO owned 669,642 shares meaning that the stake was reduced by 0.89% with the 6,000 share sell-off.

The shares most recently traded at $30.79, up $0.18, or 0.59% since the insider transaction. Historical insider transactions for Carrizo Oil & Gas go as follows:

  • 24-Week # shares sold: 1,080

The average volume for Carrizo Oil & Gas has been 805,700 shares per day over the past 30 days. Carrizo Oil & Gas has a market cap of $1.2 billion and is part of the basic materials sector and energy industry. Shares are up 43.69% year to date as of the close of trading on Monday.

Carrizo Oil & Gas, Inc., an independent energy company, engages in the exploration, development, and production of oil and gas primarily in the United States. The company has a P/E ratio of 28.1. Currently there are 9 analysts that rate Carrizo Oil & Gas a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRZO - FREE

TheStreet Quant Ratings rates Carrizo Oil & Gas as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and a generally disappointing performance in the stock itself. Get the full Carrizo Oil & Gas Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Boger Joshua S who is Director at VERTEX PHARM bought 316,086 shares at $33.89 per share for a total value of $124,971.00 on July 3, 2013. Following this transaction, the Director owned 1.3 million shares meaning that the stake was boosted by 31.03% with the 316,086 share acquisition.

The shares most recently traded at $79.31, down $1.07, or 1.33% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,300
  • 12-Week # shares sold: 91,720
  • 24-Week # shares sold: 91,720

The average volume for Vertex Pharmaceuticals has been 2.5 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $18.3 billion and is part of the health care sector and drugs industry. Shares are up 96.73% year to date as of the close of trading on Monday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Starbucks Surprises With U.S. Sales Up 2%

Starbucks Surprises With U.S. Sales Up 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company